Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.72 |
| ▸ | PGR | P06401 | 11/20 | 0.72 |
| ▸ | AR | P10275 | 8/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.72 |
| ▸ | ESR1 | P03372 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | THPO | P40225 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aglepristone SCHEMBL2108967 | 1.00 | NR3C1 (0.72) | NR3C1PGRARCYP3A4CYP2D6 | |
| Aglepristone SCHEMBL16673291 | 1.00 | NR3C1 (0.72) | NR3C1PGRARCYP3A4CYP2D6 | |
| Aglepristone SCHEMBL13625155 | 1.00 | NR3C1 (0.72) | NR3C1PGRARCYP3A4CYP2D6 | |
| SCHEMBL9359259 | 0.94 | NR3C1 (0.71) | NR3C1PGRARCYP3A4CYP2D6 | |
| SCHEMBL9847474 | 0.94 | NR3C1 (0.71) | NR3C1PGRARCYP3A4CYP2D6 | |
| SCHEMBL20621627 | 0.92 | NR3C1 (0.73) | NR3C1PGRARCYP3A4CYP2D6 | |
| Lilopristone SCHEMBL21740506 | 0.92 | PGR (0.71) | NR3C1PGRARCYP3A4CYP2D6 | |
| Lilopristone SCHEMBL21010775 | 0.92 | PGR (0.71) | NR3C1PGRARCYP3A4CYP2D6 | |
| Lilopristone SCHEMBL21740509 | 0.92 | PGR (0.71) | NR3C1PGRARCYP3A4CYP2D6 | |
| Lilopristone SCHEMBL10453406 | 0.92 | PGR (0.71) | NR3C1PGRARCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0446124-A2 | Use of antiprogestomimetics to synchronise parturition in livestock | ROUSSEL UCLAF (FR) | 1991-09-11 | — | — | EP | claimed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-15 | — | — | US | disclosed |
| US-20200054649-A1 | SKELETAL MUSCLE HYPERTROPHY INDUCERS | CYTOO (FR) | 2020-02-20 | — | — | US | disclosed |
| US-20150285803-A1 | SYSTEMS AND METHODS FOR IDENTIFYING PROGESTERONE RECEPTOR SUBTYPES | INVIVIS PHARMACEUTICALS INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-0446124-A2 | Use of antiprogestomimetics to synchronise parturition in livestock | ROUSSEL UCLAF (FR) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | NR3C1 20/4885PGR 28/4885AR 9/4885 |
| US-20200054649-A1 | SKELETAL MUSCLE HYPERTROPHY INDUCERS | TNNC1, MSTN, MTPN | NR3C1 209/4885PGR 2393/4885AR 2302/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | NR3C1 715/4885PGR 2951/4885AR 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.